Abstracts Archive - Page 2032 of 2607 - ACR Meeting Abstracts

Abstract Number: 2424 • 2015 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program
Alexei A. Grom¹, Hermine I. Brunner¹, Nicolino Ruperto², Alberto Martini², Daniel Lovell^1,3, Virginia Pascual⁴, Karine Lheritier⁵, Karolynn Leon⁶, Ken Abrams⁶ and Norman Ilowite⁷, ¹PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genova, Italy, ³Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Baylor Institute for Immunology Research, Dallas, TX, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Pediatrics, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Macrophage activation syndrome (MAS), a potentially fatal complication of systemic juvenile idiopathic arthritis (SJIA), was reported as an adverse event in both canakinumab and…
Abstract Number: 2425 • 2015 ACR/ARHP Annual Meeting
Safety of Tocilizumab in Young Adults with Juvenile Idiopathic Arthritis (JIA)
Jens Klotsche¹, Martina Niewerth², Johannes Peter Haas³, Angela Zink⁴, Gerd Horneff⁵ and Kirsten Minden⁶, ¹Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, ²Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁴Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany
Background/Purpose: Tocilizumab was recently approved for the treatment of systemic JIA (sJIA) and polyarticular JIA (pJIA). Published data on the tolerability of tocilizumab in patients…
Abstract Number: 2426 • 2015 ACR/ARHP Annual Meeting
Medication Taper and Risk of Relapse in Pediatric Uveitis
Sheila T. Angeles-Han^1,2,3, Courtney McCracken³, Steven Yeh², Daneka Stryker⁴, Kirsten Jenkins¹, Steven Tommasello⁵, Scott R. Lambert², Carolyn Drews-Botsch⁶ and Sampath Prahalad⁷, ¹Children's Healthcare of Atlanta, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁵University of Alabama, Birmingham, AL, ⁶Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁷Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA
Background/Purpose: Pediatric uveitis can be vision-threatening. Treatment typically consists of ocular steroids, methotrexate, and anti-tumor necrosis factor (TNF) agents. Optimal duration of treatment and risk…
Abstract Number: 2427 • 2015 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Mycophenolate Mofetil in Childhood Primary Central Nervous System Vasculitis
Alice Brambilla¹, Alessandra Cosi², Anna Rosati², Renzo Guerrini², Rolando Cimaz¹ and Gabriele Simonini¹, ¹Pediatric Rheumatology, Pediatric Rheumatology Unit, Anna Meyer Children's Hospital-University of Florence, Firenze, Italy, ²Neurology Unit, Neurology Unit, Anna Meyer Children's Hospital-University of Florence, Firenze, Italy
Background/Purpose: Childhood primary central nervous system vasculitis (cPANCS) is an inflammatory brain disease targeting either small (angiography-negative) or medium-large (angiography-positive) central nervous system vessels. Vascular…
Abstract Number: 2428 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab in Adult Patients with Polyarticular Juvenille Idiopathic Arthritis
Daniel Lovell^1,2, Nicolino Ruperto³, Andreas Reiff⁴, Lawrence Jung⁵, Katerina Jarosova⁶, Pierre Quartier⁷, Christy Sandborg⁸, John F. Bohnsack⁹, Dirk Elewaut¹⁰, Ivan Foeldvari¹¹, Joseph Rovensky¹², Edward H. Giannini², Nupun A. Varothai¹³, Jasmina Kalabic¹³ and Alberto Martini^14,15,16, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRCSG, Cincinnati, OH, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ⁴Children's Hospital, Los Angeles, CA, ⁵Pediatric Rheumatology, Children's National Med Ctr, Washington, DC, ⁶Revmatologicky ustav, Prague, Czech Republic, ⁷Hospital Necker Enfants Malades, Paris, France, ⁸Stanford University Medical Center, Standford, CA, ⁹Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁰Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, ¹¹Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ¹²The National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹³AbbVie, North Chicago, IL, ¹⁴University of Genova, Genova, Italy, ¹⁵Department of Pediatrics, University of Genova, Genova, Italy, ¹⁶Istituto Gaslini-PRINTO, Genova, Italy
Background/Purpose: The diagnosis of polyarticular JIA (pJIA) is made in childhood but the disease and the diagnosis are carried into adulthood. Adults with pJIA have…
Abstract Number: 2429 • 2015 ACR/ARHP Annual Meeting
Varicella Vaccination in Patients with Pediatric Rheumatic Diseases Receiving Immunosuppression: Proposal of a Pre-Vaccination Checklist to Ensure Safety
Fabian Speth¹, Johannes Peter Haas¹, Susanne Loeber¹ and Claas Hinze², ¹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ²Department of Pediatric Rheumatology and Immunology, University Hospital Münster, Münster, Germany
Background/Purpose: Varicella zoster virus (VZV) infection is a serious preventable infection in patients (pts) receiving immunosuppression (IS). The purpose of this study was to determine…
Abstract Number: 2430 • 2015 ACR/ARHP Annual Meeting
Immunological Risk Factors after Rituximab Therapy in Patients with Pediatric Rheumatic Diseases – a Prospective Single-Center Study
Fabian Speth¹, Johannes Peter Haas¹ and Claas Hinze², ¹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ²Department of Pediatric Rheumatology and Immunology, University Hospital Münster, Münster, Germany
Background/Purpose: Rituximab (RTX) is used in refractory pediatric rheumatic diseases (PRD). Data regarding the effects of RTX on the immune system in children and safety…
Abstract Number: 2431 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis
Daniel Lovell¹, Nicolino Ruperto², Daniel J. Kingsbury¹, Rubén Burgos-Vargas², Tomoyuki Imagawa³, G Horneff², Pierre Quartier⁴, Steven Goodman¹, Andreas Reiff¹, Edward H. Giannini¹, Anabela Cardoso⁵, Jaclyn K. Anderson⁶, Nupun A. Varothai⁶, Jasmina Kalabic⁶ and Alberto Martini², ¹PRCSG, Cincinnati, OH, ²PRINTO, IRCCS G. Gaslini, Genova, Italy, ³Kanagawa Children’s Medical Center, Yokohama City, Japan, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie, Amadora, Portugal, ⁶AbbVie, North Chicago, IL
Background/Purpose: The long-term safety of anti-tumor necrosis factor (TNF) drugs is particularly important in pediatric patients (pts) who may require prolonged treatment of their inflammatory…
Abstract Number: 2432 • 2015 ACR/ARHP Annual Meeting
The Preventive Effect of Methotrexate on Uveitis Onset in JIA Depends on Uveitis Risk Factors
Mikhail Kostik¹, Ekaterina Gaidar¹, Margarita Dubko¹, Ludmila Snegireva², Vera Masalova², Irina Chikova¹, Eugenia Isupova³, Tatiana Nikitina⁴, Elena Serogodskaya¹, Olga Kalashnikova¹, Angelo Ravelli⁵ and Vyacheslav Chasnyk³, ¹State Pediatric Medical University, Saint-Petersburg, Russia, ²Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ³Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, ⁴State Pediatric Medical University, St. Petersburg, Russia, ⁵Pediatria-II, IRCCS G. Gaslini and University of Genova, Genova, Italy
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The main predictors of uveitis…
Abstract Number: 2433 • 2015 ACR/ARHP Annual Meeting
Anti Interferon-Gamma (IFNg) Monoclonal Antibody Treatment in a Child with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)
Claudia Bracaglia¹, Giusi Prencipe¹, Antonio Gatto², Manuela Pardeo¹, Geneviève Lapeyre³, Luigi Raganelli¹, Emiliano Marasco², Antonella Insalaco², Walter Ferlin³, Robert Nelson³, Cristina de Min³ and Fabrizio De Benedetti¹, ¹Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ²Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ³NovImmune S.A., Geneva, Switzerland
Background/Purpose: Animal and humans data suggest that IFNγ plays a pathogenic role in HLH. A pilot trial in primary HLH with NI-0501, an anti-IFNγ monoclonal…
Abstract Number: 2434 • 2015 ACR/ARHP Annual Meeting
Promis Tools for Measurement of Patient-Reported Outcomes in Children with Juvenile Arthritis
Timothy Brandon¹, Brandon Becker¹, Katherine Bevans¹ and Pamela F. Weiss², ¹Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ²Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Child/parent perspectives on their own/their child's health are highly pertinent to disease management. PROMIS is a collection of patient-reported outcome measures that were developed…
Abstract Number: 2435 • 2015 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Adult Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
Katerina Jarosova¹, Katerina Andelova², Karel Hejduk³, Michal Uher³ and Jiri Vencovsky⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²clinical, Institute for the Care for Mother and Child, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic
Background/Purpose: Biologic drugs are effective therapeutic option in patients with juvenile idiopathic arthritis (JIA). However, data regarding the use during pregnancy and breastfeeding in adult…
Abstract Number: 2436 • 2015 ACR/ARHP Annual Meeting
Views and Prescribing Habits of Pneumocystis Prophylaxis in the Pediatric Rheumatology Community
Matthew Basiaga¹, Alexis Ogdie-Beatty² and for the CARRA Investigators, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Pneumocystis pneumonia (PCP) is a potentially devastating opportunistic infection. The incidence of PCP and the risk of adverse events secondary to prophylactic medication in…
Abstract Number: 2437 • 2015 ACR/ARHP Annual Meeting
Experience with Tocilizumab for Treatment of 56 Children with Systemic Juvenile Idiopathic Arthritis in the German JIA Biologics Register
Gerd Horneff¹, Gerd Ganser², Johannes Peter Haas³, Toni Hospach⁴, Ralf Trauzeddel⁵, Hans-Iko Huppertz⁶, J B. Kuemmerle-Deschner⁷, Kirsten Minden⁸ and BIKER Registry Study Group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁴Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁵HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁶PRINTO, IRCCS G. Gaslini, Genoa, Italy, ⁷Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁸DRFG, Berlin, Germany
Background/Purpose: Tocilizumab (TOC) has become a valuable option for treatment of systemic juvenile idiopathic arthritis (sJIA), which significantly improved the outcome of patients. The aim…
Abstract Number: 2438 • 2015 ACR/ARHP Annual Meeting
Clinical Examination of the Temporomandibular Joint; A Eurotmjoint Initiative
Bernd Koos¹, Peter Stoustrup², Lynn R. Spiegel³, Nikolay Tzaribachev⁴, Troels Herlin⁵, Thomas Klit Pedersen⁶ and Marinka Twilt⁷, ¹Orthodontics, University of Rostock, Rostock, Germany, ²Section of Orthodontics, University of Aarhus, Aarhus C, Denmark, ³Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatric Rheumatology, Center for Rheumatic Diseases, Bad Bramstedt, Germany, ⁵Department of Pediatrics, Århus University Hospital Skejby, Århus, Denmark, ⁶orthodontics, Aarhus University Hospital/Dental school, Aarhus, Denmark, ⁷Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Arthritis of the temporomandibular joint (TMJ) in patients with Juvenile Idiopathic Arthritis (JIA) is increasingly recognized. In the last decade, studies report that the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].